Corient Private Wealth
EFTR

Corient Private Wealth’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Corient Private Wealth’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,018
Closed -$118K – 2063
2022
Q4 		$118K Buy
+11,018
New +$140K ﹤0.01% 1552

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOA
Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return

Corient Private Wealth's EFTR Position: Q1 2023 in Review

Corient Private Wealth sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2023, closing a stake of 11,018 shares — an estimated $118K sold.

Corient Private Wealth first reported a position in EFTR in Q4 2022 and held it in 1 quarter. The position peaked at $118K in Q4 2022. 26 funds tracked by Wall St. Rank hold EFTR as of Q1 2023.

  • Corient Private Wealth reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Corient Private Wealth sold 11,018 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $118K.
  • Corient Private Wealth first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Corient Private Wealth's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $118K in Q4 2022.
  • 26 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Corient Private Wealth's 13F filing for Q1 2023, filed 15 May 2023.